Skip to main content
Springer logoLink to Springer
. 2017 Nov 13;53(5):689. doi: 10.1007/s00535-017-1409-z

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Hiromitsu Kumada 1,, Tsunamasa Watanabe 2, Fumitaka Suzuki 1, Kenji Ikeda 1, Ken Sato 3, Hidenori Toyoda 4, Masanori Atsukawa 5, Akio Ido 6, Akinobu Takaki 7, Nobuyuki Enomoto 8, Koji Kato 9, Katia Alves 9, Margaret Burroughs 9, Rebecca Redman 9, David Pugatch 9, Tami J Pilot-Matias 9, Preethi Krishnan 9, Rajneet K Oberoi 9, Wangang Xie 9, Kazuaki Chayama 10
PMCID: PMC5910493  PMID: 29134328

Correction to: J Gastroenterol DOI 10.1007/s00535-017-1396-0

Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as “© The Author(s) 2017” instead of “©The Author(s) 2017 This article is an open access publication” and also the CC-BY description was not included. The description should be as follows.

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article was corrected.

Footnotes

The original article can be found online at 10.1007/s00535-017-1396-0.


Articles from Journal of Gastroenterology are provided here courtesy of Springer

RESOURCES